An update on Huntington's disease: from the gene to the clinic
- PMID: 24978638
- DOI: 10.1097/WCO.0000000000000116
An update on Huntington's disease: from the gene to the clinic
Abstract
Purpose of review: This review highlights the recent advances in Huntington's disease, with a particular focus on development of disease biomarkers for use in therapeutic trials in the premotor phase of the disease, as well as the growing literature regarding pathophysiological mechanisms and their relevance to potential therapeutic targets.
Recent findings: There have been continued advances in the development of disease biomarkers, and promising neuroprotection trials are beginning to emerge in the premotor stage of Huntington's disease. Deeper understanding of the pathophysiological mechanisms is being translated into potential therapeutic strategies.
Summary: The premotor stage of Huntington's disease provides an ideal time to trial disease-modifying therapy, but reliable biomarkers are required for monitoring disease progression, and this remains an area of intense research. Our understanding of the underlying pathophysiological mechanisms continues to expand, and a number of promising therapeutic strategies are emerging, including strategies to silence mutant huntingtin expression.
Similar articles
-
Huntington's disease.Curr Opin Neurol. 2012 Aug;25(4):491-8. doi: 10.1097/WCO.0b013e3283550c97. Curr Opin Neurol. 2012. PMID: 22772878 Review.
-
Update on Huntington's disease: advances in care and emerging therapeutic options.Parkinsonism Relat Disord. 2015 Mar;21(3):169-78. doi: 10.1016/j.parkreldis.2014.12.013. Epub 2014 Dec 19. Parkinsonism Relat Disord. 2015. PMID: 25572500 Review.
-
Investigational agents for the management of Huntington's disease.Expert Opin Investig Drugs. 2017 Feb;26(2):175-185. doi: 10.1080/13543784.2017.1270266. Epub 2016 Dec 16. Expert Opin Investig Drugs. 2017. PMID: 27927041 Review.
-
Development of biomarkers for Huntington's disease.Lancet Neurol. 2011 Jun;10(6):573-90. doi: 10.1016/S1474-4422(11)70070-9. Lancet Neurol. 2011. PMID: 21601164 Review.
-
[Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges].Rev Med Brux. 2007 Nov-Dec;28(6):487-94. Rev Med Brux. 2007. PMID: 18265808 Review. French.
Cited by
-
Spectrum of tau pathologies in Huntington's disease.Lab Invest. 2019 Jul;99(7):1068-1077. doi: 10.1038/s41374-018-0166-9. Epub 2018 Dec 20. Lab Invest. 2019. PMID: 30573872 Free PMC article.
-
Deregulation of RNA Metabolism in Microsatellite Expansion Diseases.Adv Neurobiol. 2018;20:213-238. doi: 10.1007/978-3-319-89689-2_8. Adv Neurobiol. 2018. PMID: 29916021 Free PMC article. Review.
-
Creatine as a Neuroprotector: an Actor that Can Play Many Parts.Neurotox Res. 2019 Aug;36(2):411-423. doi: 10.1007/s12640-019-00053-7. Epub 2019 May 8. Neurotox Res. 2019. PMID: 31069754 Review.
-
Bibliography: Clinical Neuropsychiatry.Focus (Am Psychiatr Publ). 2016 Oct;14(4):488-489. doi: 10.1176/appi.focus.140404. Epub 2016 Oct 7. Focus (Am Psychiatr Publ). 2016. PMID: 31975831 Free PMC article. No abstract available.
-
Features of the Influence of a DNA Sequence on Its Adjacent Sequence.ACS Omega. 2020 Sep 5;5(37):23631-23644. doi: 10.1021/acsomega.0c02264. eCollection 2020 Sep 22. ACS Omega. 2020. PMID: 32984683 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials